Richard Flanagan has been named president of DRAXIS’ radiopharmaceutical subsidiary, DRAXIMAGE. He has succeeded Ray Dore, who plans to retire in September but will continue to serve as a special advisor. Flanagan, who is currently executive vice
Richard Flanagan has been named president of DRAXIS’ radiopharmaceutical subsidiary, DRAXIMAGE. He has succeeded Ray Dore, who plans to retire in September but will continue to serve as a special advisor. Flanagan, who is currently executive vice president, has been with DRAXIMAGE since its founding in 1997.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.